Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : Hoth save search
Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients
Published: 2024-01-18 (Crawled : 00:00) - biospace.com/
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 5.43%
H: 13.24%
C: 0.74%
ht-001 fda approval treat trial therapeutics
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami
Published: 2023-12-27 (Crawled : 13:30) - prnewswire.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 16.3%
H: 10.19%
C: 2.55%
ht-001 fda cleared cancer expansion trial therapeutics
Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa
Published: 2023-09-06 (Crawled : 14:00) - biospace.com/
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 4.61%
H: 2.2%
C: 0.88%
positive trial therapeutics results
Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial
Published: 2023-07-25 (Crawled : 13:00) - biospace.com/
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 1.15%
H: 2.27%
C: 1.89%
trial therapeutics milestone
Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical Site
Published: 2023-06-14 (Crawled : 22:00) - biospace.com/
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 1.0%
H: 8.94%
C: 6.62%
ht-001 fda cleared approval trial therapeutics
Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
Published: 2023-03-08 (Crawled : 17:00) - biospace.com/
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: -0.37%
H: 4.49%
C: 2.62%
active collaboration trial therapeutics therapy cancer growth
Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
Published: 2023-01-25 (Crawled : 15:20) - biospace.com/
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: -1.76%
H: 2.79%
C: 2.79%
trial therapeutics therapy cancer growth
HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS
Published: 2022-10-31 (Crawled : 14:20) - prnewswire.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: -0.44%
H: 39.57%
C: -1.06%
dermatitis trial therapeutics positive results phase 2b
Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis
Published: 2022-06-21 (Crawled : 17:00) - prnewswire.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 5.26%
H: 0.0%
C: 0.0%
australia dermatitis trial approval therapeutics
Hoth Therapeutics Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient Cohort
Published: 2022-05-03 (Crawled : 12:20) - prnewswire.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: -5.44%
H: 6.76%
C: 6.2%
dermatitis trial therapeutics phase 2b
Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way
Published: 2021-11-30 (Crawled : 13:00) - ir.hoththerapeutics.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 0.06%
H: 4.32%
C: -1.8%
atopic dermatitis phase 1 dermatitis phase 1b trial therapeutics enroll phase 2b
Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis Patients
Published: 2021-10-12 (Crawled : 14:00) - ir.hoththerapeutics.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 0.0%
H: 12.17%
C: 0.87%
treatment dermatitis trial approval atopic dermatitis xin
Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial
Published: 2021-09-21 (Crawled : 14:00) - ir.hoththerapeutics.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 1.68%
H: 9.09%
C: -0.83%
trial approval xin
Hoth Therapeutics Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa
Published: 2021-09-08 (Crawled : 12:00) - ir.hoththerapeutics.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: -1.49%
H: 1.52%
C: 1.52%
phase 1 positive results trial phase 1b phase 2b
Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis
Published: 2021-06-28 (Crawled : 12:00) - ir.hoththerapeutics.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 1.26%
H: 4.97%
C: -1.86%
treatment phase 1 positive results dermatitis trial atopic dermatitis phase 1b al001 adi-001 phase 2b
Hoth Therapeutics' First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is Underway
Published: 2021-04-22 (Crawled : 14:00) - biospace.com/
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 0.0%
H: 4.58%
C: -0.65%
treatment dermatitis trial atopic dermatitis
Hoth Therapeutics Completes HT-001 Formulation Development for Upcoming Cancer Patient Clinical Trial
Published: 2021-04-12 (Crawled : 15:00) - biospace.com/
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 2.25%
H: 1.65%
C: -8.79%
cancer trial
Hoth Therapeutics Engages Worldwide Clinical Trials as Contract Research Organization for Phase 2a HT-001 Clinical Trial for Cancer Patients
Published: 2021-04-06 (Crawled : 13:35) - prnewswire.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: -1.4%
H: 0.0%
C: -6.64%
phase 2 clinical trials cancer contract research trial phase 2b
Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis
Published: 2021-03-01 (Crawled : 21:00) - biospace.com/
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 0.0%
H: 5.02%
C: -1.7%
treatment dermatitis trial atopic dermatitis
Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans
Published: 2020-12-10 (Crawled : 16:00) - biospace.com/
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 4.24%
H: 16.28%
C: 6.98%
dermatitis trial approval treatment atopic dermatitis phase 1b phase 2b
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.